Peptilogics, Pittsburgh, USA
www.peptilogics.com

PLG0206
NOVEL CLASS OF DIRECT-ACTING ENGINEERED PEPTIDES
Antibiotic
Peptilogics is developing unique engineered peptide-based antibiotics to address difficult-to-treat infections, including those caused by or containing a bacterial biofilm component associated with prosthetic joint infections (PJI). The lead compound, PLG0206, is a broad-spectrum agent with activity against the critical ESKAPE pathogens, with an initial focus on the predominant causative agents found in wound, surgical site, and implant-associated infections. The CARB-X award will support the development of PLG0206 including the filing of a US FDA Investigational New Drug Application, leading to a Phase 1 clinical study in patients. Peptilogics’ program has been granted Qualified Infectious Disease Product (QIDP) status and Orphan Drug Designation by the FDA.

The number of knee, hip and other joint replacements around the world is growing every year. In the US alone, more than 1 million total joint replacements are performed annually, a number expected to grow to 4 million by 2030.

Current Development Stage: Phase 1

CARB-X Investment: Initial investment of up to $2.56m with potential option payments up to $9.61m.

Initial CARB-X Investment Date: January 1, 2020

Read the Spotlight feature about Peptilogics.